Stockscreener 앱 받기
4.2918
2.26%
-0.1382
전일 마감가:
$4.43
열려 있는:
$4.26
하루 거래량:
70,469
Relative Volume:
0.11
시가총액:
$469.02M
수익:
-
순이익/손실:
$-299.80M
주가수익비율:
-0.354
EPS:
-12.1221
순현금흐름:
$-217.49M
1주 성능:
-16.09%
1개월 성능:
-29.94%
6개월 성능:
+0.00%
1년 성능:
-49.77%
1일 변동 폭
$4.24
$4.44
1주일 범위
$4.24
$5.19
52주 변동 폭
$3.36
$8.885
Acelyrin Inc Stock (SLRN) Company Profile
명칭
Acelyrin Inc
전화
805-871-4300
주소
4149 LIBERTY CANYON RD., AGOURA HILLS
SLRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SLRN | 4.30 | 469.02M | 0 | -299.80M | -217.49M | -12.12 |
| VRTX | 446.61 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.00 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.23 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.42 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-09-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | 개시 | H.C. Wainwright | Buy |
| 2023-05-30 | 개시 | Jefferies | Buy |
| 2023-05-30 | 개시 | Morgan Stanley | Overweight |
| 2023-05-30 | 개시 | Piper Sandler | Overweight |
| 2023-05-30 | 개시 | TD Cowen | Outperform |
모두보기
Acelyrin Inc 주식(SLRN)의 최신 뉴스
HC Wainwright Issues Positive Estimate for Acelyrin Earnings - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call Transcript - Insider Monkey
TD Cowen maintains Buy rating on Acelyrin shares By Investing.com - Investing.com Canada
Acelyrin discloses ValenzaBio acquisition financials - Investing.com India
TD Cowen maintains Buy rating on Acelyrin shares - Investing.com
T. Rowe Price Investment Management, Inc. Reduces Stake in Acely - GuruFocus.com
Earnings call: Acelyrin focuses on TED treatment, eyes Phase 3 trials - Investing.com
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ... By GuruFocus - Investing.com Canada
ACELYRIN, INC. Advances Key Drug Developments - TipRanks
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - The Manila Times
ACELYRIN Reports $562M Cash Position, Advances Key Clinical Trials Amid Pipeline Focus | SLRN Stock News - StockTitan
(SLRN) Investment Analysis and Advice - Stock Traders Daily
Acelyrin (SLRN) Set to Announce Earnings on Wednesday - MarketBeat
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 - The Manila Times
ACELYRIN Sets Q3 2024 Earnings Call: Immunology Pipeline Updates Coming Nov 13 | SLRN Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Acelyrin Inc Shares - GuruFocus.com
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(SLRN) Proactive Strategies - Stock Traders Daily
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat
The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat
(SLRN) Trading Advice - Stock Traders Daily
Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat
SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan
Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times
Did Acelyrin Inc (SLRN) perform well in the last session? - US Post News
Acelyrin (NASDAQ:SLRN) Stock Price Down 2.4%Should You Sell? - MarketBeat
Acelyrin Inc (SLRN) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Up 5.9%Still a Buy? - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Millennium Management LLC Has $20.47 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Renaissance Technologies LLC Has $1.75 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
160,167 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Susquehanna Fundamental Investments LLC - Defense World
Susquehanna Fundamental Investments LLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Recent Insider Activity Suggests Potential Gains for Acelyrin Inc (SLRN) - Knox Daily
Almitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Piper Sandler maintains Overweight rating on Acelyrin shares - Investing.com
Piper Sandler maintains Overweight rating on Acelyrin shares By Investing.com - Investing.com Australia
Acelyrin Inc [SLRN] Director makes an insider sale of 1 shares worth $7.0. - Knox Daily
Top investors say Acelyrin Inc (SLRN) ticks everything they need - SETE News
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12% - Simply Wall St
Can Acelyrin Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Down 5.4% - MarketBeat
How did Acelyrin Inc (SLRN) fare last session? - US Post News
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch (NASDAQ:SLRN) - Seeking Alpha
Acelyrin (NASDAQ:SLRN) Shares Gap Up to $4.60 - MarketBeat
Acelyrin stock spikes on upcoming presentation (NASDAQ:SLRN) - Seeking Alpha
Acelyrin announces positive results from Phase 3 trial of izokibep - TipRanks
Acelyrin Inc (SLRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acelyrin Inc 주식 (SLRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | Chief Executive Officer |
Apr 01 '24 |
Sale |
6.63 |
9,961 |
66,024 |
1,577,374 |
| Lin Shao-Lee | Chief Executive Officer |
Feb 20 '24 |
Sale |
7.60 |
15,701 |
119,403 |
1,587,335 |
| Lin Shao-Lee | Chief Executive Officer |
Jan 02 '24 |
Sale |
7.41 |
10,691 |
79,188 |
1,603,036 |
0.42%
0.16%
자본화:
|
볼륨(24시간):